A microbial polysaccharide reduces the severity of rheumatoid arthritis by influencing Th17 differentiation and proinflammatory cytokines production

Journal of Immunology

Volumn 183, Issue 1, 2009, Pages 191-200

  Monari, Claudia ^a   Bevilacqua, Sara ^a   Piccioni, Miranda ^a   Pericolini, Eva ^a   Perito, Stefano ^a   Calvitti, Mario ^a   Bistoni, Francesco ^a   Kozel, Thomas R ^b   Vecchiarelli, Anna ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GLUCURONOXYLOMANNAN; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 6; LYMPHOTOXIN; RETINOIC ACID RECEPTOR GAMMA; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; AUTACOID; COLLAGEN TYPE 2; CYTOKINE; FUNGUS ANTIGEN; IMMUNOSUPPRESSIVE AGENT; OSTEOCLAST DIFFERENTIATION FACTOR; POLYSACCHARIDE; TNFSF11 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; DISEASE SEVERITY; DOWN REGULATION; DRUG EFFECT; JOINT INJURY; LYMPHOCYTE DIFFERENTIATION; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RHEUMATOID ARTHRITIS; TH17 CELL; UPREGULATION; ANIMAL; ARTHRITIS; BIOSYNTHESIS; CRYPTOCOCCUS NEOFORMANS; DBA MOUSE; DRUG ANTAGONISM; GENETICS; HELPER CELL; HOSPITALIZATION; IMMUNOLOGY; INCIDENCE; METABOLISM; OSTEOCLAST; OSTEOLYSIS; PATHOLOGY; PHYSIOLOGY;

ANIMALS; ANTIGENS, FUNGAL; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; BONE RESORPTION; COLLAGEN TYPE II; CRYPTOCOCCUS NEOFORMANS; CYTOKINES; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; INFLAMMATION MEDIATORS; INTERLEUKIN-17; MALE; MICE; MICE, INBRED DBA; OSTEOCLASTS; POLYSACCHARIDES; RANK LIGAND; SEVERITY OF ILLNESS INDEX; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 68949145033     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0804144     Document Type: Article

References (49)

1. Lee, D. M., and M. E. Weinblatt. 2001. Rheumatoid arthritis. Lancet 358: 903-911.
2. Goronzy, J. J., and C. M. Weyand. 2005. Rheumatoid arthritis. Immunol. Rev. 204: 55-73.
3. McInnes, I. B., and G. Schett. 2007. Cytokines in the pathogenesis of rheumatoid arthritis. Nat. Rev. Immunol. 7: 429-442.
4. Mugnier, B., and J. Roudier. 2004. Factors predicting responsiveness to anti-TNFα therapy in patients with rheumatoid arthritis: using biotherapies rationally. Joint Bone Spine 71: 91-94. (Pubitemid 38407213)
5. Lubberts, E. 2008. IL-17/Th17 targeting: on the road to prevent chronic destructive arthritis? Cytokine 41: 84-91.
6. Miossec, P. 2003. Interleukin-17 in rheumatoid arthritis: if T cells were to contribute to inflammation and destruction through synergy. Arthritis Rheum. 48: 594-601.
7. Stockinger, B., and M. Veldhoen. 2007. Differentiation and function of Th17 T cells. Curr. Opin. Immunol. 19: 281-286.
8. Dong, C. 2008. TH17 cells in development: an updated view of their molecular identity and genetic programming. Nat. Rev. Immunol. 8: 337-348.
9. Hwang, S. Y., and H. Y. Kim. 2005. Expression of IL-17 homologs and their receptors in the synovial cells of rheumatoid arthritis patients. Mol. Cells 19: 180-184.
10. Chabaud, M., J. M. Durand, N. Buchs, F. Fossiez, G. Page, L. Frappart, and P. Miossec. 1999. Human interleukin-17: a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum. 42: 963-970.
11. Chabaud, M., E. Lubberts, L. Joosten, W. van Den Berg, and P. Miossec. 2001. IL-17 derived from juxta-articular bone and synovium contributes to joint degradation in rheumatoid arthritis. Arthritis Res. 3: 168-177.
12. Cho, Y. G., M. L. Cho, S. Y. Min, and H. Y. Kim. 2007. Type II collagen autoimmunity in a mouse model of human rheumatoid arthritis. Autoimmun. Rev. 7: 65-70.
13. Retini, C., A. Vecchiarelli, C. Monari, F. Bistoni, and T. R. Kozel. 1998. Encapsulation of Cryptococcus neoformans with glucuronoxylomannan inhibits the antigen-presenting capacity of monocytes. Infect. Immun. 66: 664-669. (Pubitemid 28074210)
14. Monari, C., T. R. Kozel, A. Casadevall, D. Pietrella, B. Palazzetti, and A. Vecchiarelli. 1999. B7 costimulatory ligand regulates development of the T-cell response to Cryptococcus neoformans. Immunology 98: 27-35. (Pubitemid 29425905)
15. Pietrella, D., C. Monari, C. Retini, B. Palazzetti, T. R. Kozel, and A. Vecchiarelli. 1999. HIV type 1 envelope glycoprotein gp120 induces development of a T helper type 2 response to Cryptococcus neoformans. AIDS 13: 2197-2207.
16. Vecchiarelli, A., C. Monari, C. Retini, D. Pietrella, B. Palazzetti, L. Pitzurra, and A. Casadevall. 1998. Cryptococcus neoformans differently regulates B7-1 (CD80) and B7-2 (CD86) expression on human monocytes. Eur. J. Immunol. 28: 114-121.
17. Monari, C., F. Bistoni, A. Casadevall, E. Pericolini, D. Pietrella, T. R. Kozel, and A. Vecchiarelli. 2005. Glucuronoxylomannan, a microbial compound, regulates expression of costimulatory molecules and production of cytokines in macrophages. J. Infect. Dis. 191: 127-137.
18. Vecchiarelli, A., D. Pietrella, P. Lupo, F. Bistoni, D. C. McFadden, and A. Casadevall. 2003. The polysaccharide capsule of Cryptococcus neoformans interferes with human dendritic cell maturation and activation. J. Leukocyte Biol. 74: 370-378.
19. Retini, C., A. Casadevall, D. Pietrella, C. Monari, B. Palazzetti, and A. Vecchiarelli. 1999. Specific activated T cells regulate IL-12 production by human monocytes stimulated with Cryptococcus neoformans. J. Immunol. 162: 1618-1623. (Pubitemid 29307037)
20. Monari, C., E. Pericolini, G. Bistoni, A. Casadevall, T. R. Kozel, and A. Vecchiarelli. 2005. Cryptococcus neoformans capsular glucuronoxylomannan induces expression of Fas ligand in macrophages. J. Immunol. 174: 3461-3468. (Pubitemid 40354053)
21. Monari, C., F. Paganelli, F. Bistoni, T. R. Kozel, and A. Vecchiarelli. 2008. Capsular polysaccharide induction of apoptosis by intrinsic and extrinsic mechanisms. Cell. Microbiol. 10: 2129-2137.
22. Vecchiarelli, A., C. Retini, D. Pietrella, C. Monari, C. Tascini, T. Beccari, and T. R. Kozel. 1995. Downregulation by cryptococcal polysaccharide of tumor necrosis factor alpha and interleukin-1β secretion from human monocytes. Infect. Immun. 63: 2919-2923.
23. Vecchiarelli, A., C. Retini, C. Monari, C. Tascini, F. Bistoni, and T. R. Kozel. 1996. Purified capsular polysaccharide of Cryptococcus neoformans induces interleukin-10 secretion by human monocytes. Infect. Immun. 64: 2846-2849. (Pubitemid 26226860)
24. Retini, C., T. R. Kozel, D. Pietrella, C. Monari, F. Bistoni, and A. Vecchiarelli. 2001. Interdependency of interleukin-10 and interleukin-12 in regulation of T-cell differentiation and effector function of monocytes in response to stimulation with Cryptococcus neoformans. Infect. Immun. 69: 6064-6073.
25. Tissi, L., M. Puliti, F. Bistoni, P. Mosci, T. R. Kozel, and A. Vecchiarelli. 2004. Glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans, inhibits the progression of group B streptococcal arthritis. Infect. Immun. 72: 6367-6372.
26. Cherniak, R., E. Reiss, M. E. Slodki, R. D. Plattner, and S. O. Blumer. 1980. Structure and antigenic activity of the capsular polysaccharide of Cryptococcus neoformans serotype A. Mol. Immunol. 17: 1025-1032.
27. Houpt, D. C., G. S. Pfrommer, B. J. Young, T. A. Larson, and T. R. Kozel. 1994. Occurrences, immunoglobulin classes, and biological activities of antibodies in normal human serum that are reactive with Cryptococcus neoformans glucuronoxylomannan. Infect. Immun. 62: 2857-2864.
28. Cuzzocrea, S., E. Ayroldi, R. Di Paola, M. Agostini, E. Mazzon, S. Bruscoli, T. Genovese, S. Ronchetti, A. P. Caputi, and C. Riccardi. 2005. Role of glucocorticoid-induced TNF receptor family gene (GITR) in collagen-induced arthritis. FASEB J. 19: 1253-1265.
29. Pericolini, E., E. Cenci, E. Gabrielli, S. Perito, P. Mosci, F. Bistoni, and A. Vecchiarelli. 2008. Indinavir influences biological function of dendritic cells and stimulates antifungal immunity. J. Leukocyte Biol. 83: 1286-1294.
30. Trinchieri, G. 1993. Interleukin-12 and its role in the generation of TH1 cells. Immunol. Today 14: 335-338.
31. Trinchieri, G. 1997. Function and clinical use of interleukin-12. Curr. Opin. Hematol. 4: 59-66.
32. Sato, K., A. Suematsu, K. Okamoto, A. Yamaguchi, Y. Morishita, Y. Kadono, S. Tanaka, T. Kodama, S. Akira, Y. Iwakura, et al. 2006. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J. Exp. Med. 203: 2673-2682.
33. + regulatory T cells. Int. J. Clin. Exp. Med. 1: 192-202.
34. +CD25 T cells. J. Immunol. 179: 2041-2045.
35. Wei, W. Z., G. P. Morris, and Y. C. Kong. 2004. Anti-tumor immunity and autoimmunity: a balancing act of regulatory T cells. Cancer Immunol. Immunother. 53: 73-78.
36. Harris, T. J., J. F. Grosso, H. R. Yen, H. Xin, M. Kortylewski, E. Albesiano, E. L. Hipkiss, D. Getnet, M. V. Goldberg, C. H. Maris, et al. 2007. Cutting edge: an in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunity. J. Immunol. 179: 4313-4317.
37. + T helper cells. Cell 126: 1121-1133.
38. Vecchiarelli, A. 2000. Immunoregulation by capsular components of Cryptococcus neoformans. Med. Mycol. 38: 407-417. (Pubitemid 32045754)
39. Bathon, J. M., R. W. Martin, R. M. Fleischmann, J. R. Tesser, M. H. Schiff, E. C. Keystone, M. C. Genovese, M. C. Wasko, L. W. Moreland, A. L. Weaver, et al. 2000. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N. Engl. J. Med. 343: 1586-1593.
40. Lipsky, P. E., D. M. van der Heijde, E. W. St Clair, D. E. Furst, F. C. Breedveld, J. R. Kalden, J. S. Smolen, M. Weisman, P. Emery, M. Feldmann, et al. 2000. Infliximab and methotrexate in the treatment of rheumatoid arthritis: Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N. Engl. J. Med. 343: 1594-1602.
41. Bongartz, T., A. J. Sutton, M. J. Sweeting, I. Buchan, E. L. Matteson, and V. Montori. 2006. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. J. Am. Med. Assoc. 295: 2275-2285.
42. Morand, E. F. 2007. Effects of glucocorticoids on inflammation and arthritis. Curr. Opin. Rheumatol. 19: 302-307.
43. Mirshafiey, A., D. T. Ngoc Dzung, J. W. Murphy, M. R. Khorramizadeh, F. Saadat, F. Mehrabian, and P. Larsson. 2004. Tolerability and anti-inflammatory effects of glucuronoxylomannan in collagen-induced arthritis. Scand. J. Immunol. 60: 226-232.
44. Hafezi-Moghadam, A., T. Simoncini, Z. Yang, F. P. Limbourg, J. C. Plumier, M. C. Rebsamen, C. M. Hsieh, D. S. Chui, K. L. Thomas, A. J. Prorock, et al. 2002. Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase. Nat. Med. 8: 473-479.
45. Monari, C., C. Retini, A. Casadevall, D. Netski, F. Bistoni, T. R. Kozel, and A. Vecchiarelli. 2003. Differences in outcome of the interaction between Cryptococcus neoformans glucuronoxylomannan and human monocytes and neutrophils. Eur. J. Immunol. 33: 1041-1051.
46. Monari, C., T. R. Kozel, F. Paganelli, E. Pericolini, S. Perito, F. Bistoni, A. Casadevall, and A. Vecchiarelli. 2006. Microbial immune suppression mediated by direct engagement of inhibitory Fc receptor. J. Immunol. 177: 6842-6851.
47. Monari, C., F. Bistoni, and A. Vecchiarelli. 2006. Glucuronoxylomannan exhibits potent immunosuppressive properties. FEMS Yeast Res. 6: 537-542.
48. Kotake, S., N. Udagawa, N. Takahashi, K. Matsuzaki, K. Itoh, S. Ishiyama, S. Saito, K. Inoue, N. Kamatani, M. T. Gillespie, et al. 1999. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J. Clin. Invest. 103: 1345-1352.
49. Villena, S. N., R. O. Pinheiro, C. S. Pinheiro, M. P. Nunes, C. M. Takiya, G. A. DosReis, J. O. Previato, L. Mendonca-Previato, and C. G. Freire-de-Lima. 2008. Capsular polysaccharides galactoxylomannan and glucuronoxylomannan from Cryptococcus neoformans induce macrophage apoptosis mediated by Fas ligand. Cell. Microbiol. 10: 1274-1285.